Glucagonoma and Glucagonoma Syndrome: An Updated Review
Clinical Endocrinology · 2025-10 · 103 (4) · 417-426
DOI: 10.1111/cen.15300 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Endocrinology, online erschienen am 04.07.2025. Verfasst von Sofia Anelli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Endocrinology Unit, Department of Clinical and Molecular Medicine, ENETS Excellence Center, Sapienza University of Rome, Sant'Andrea Hospital, Rome, …. Hauptthemen laut MEDLINE: Glucagonoma, Pancreatic Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Glucagonoma is a rare well‐differentiated slowly proliferating pancreatic neuroendocrine tumour, characterized by several manifestations including necrolytic migratory erythema, weight loss, diabetes and anaemia.
Aim
The purpose of the current review was to acknowledge literature about this rare tumour discerning the clinical features, diagnosis, treatment and prognosis of glucagonoma by comparing three different periods.
Results
A study published by Song reviewed 216 cases from studies published between 1999 and 2016, making a comparison with 407 cases reported before 1998 by Soga and Yakuwa. The current review consisted of 86 cases reported in studies published in and after 2017: 40 males and 46 females, with an average age of 48.2 years. The male‐to‐female ratio was 0.87. The rate of typical clinical findings was as follows: NME, 93.2% (69/74); DM, 70.3% (50/74); weight loss, 62.2% (46/74); anaemia, 44.6% (33/74); glossitis or stomatitis or cheilitis, 31.1% (23/74). A total of 85 cases reported the location of the tumour as the pancreas and 38.8% of these cases involved the tail of the pancreas. The average tumour size was 4.6 cm in patients between 2017 and 2024. Metastasis was detected in 52.3% of patients (45/86). The comparison with previous series highlighted an earlier age of diagnosis of glucagonoma and a higher rate of NME, consistent with a higher diagnostic accuracy.
Conclusions
Glucagonoma is a rare pathology, with peculiar characteristics that need to be acknowledged to achieve a timely diagnosis and finally improve patient prognosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Endocrinology Unit, Department of Clinical and Molecular Medicine, ENETS Excellence Center, Sapienza University of Rome, Sant'Andrea Hospital, Rome, Italy.
- Department of Digestive Disease, ENETS Excellence Center, Sant'Andrea University Hospital, Sapienza University of Rome, Rome, Italy.
ORCID-Profile: Rossella Mazzilli
Zitieren
APA
Anelli, S., Mazzilli, R., Zamponi, V., Giorgini, B., Golisano, B., Mancini, C., Russo, F., Panzuto, F., & Faggiano, A. (2025). Glucagonoma and Glucagonoma Syndrome: An Updated Review. Clinical Endocrinology, 103(4), 417-426. https://doi.org/10.1111/cen.15300
Vancouver
Anelli S, Mazzilli R, Zamponi V, Giorgini B, Golisano B, Mancini C, et al. Glucagonoma and Glucagonoma Syndrome: An Updated Review. Clinical Endocrinology. 2025;103(4):417-426. doi:10.1111/cen.15300
BibTeX
@article{Anelli2025,
author = {Anelli, Sofia and Mazzilli, Rossella and Zamponi, Virginia and Giorgini, Beatrice and Golisano, Bianca and Mancini, Camilla and Russo, Flaminia and Panzuto, Francesco and Faggiano, Antongiulio},
title = {Glucagonoma and Glucagonoma Syndrome: An Updated Review},
journal = {Clinical Endocrinology},
year = {2025},
volume = {103},
number = {4},
pages = {417--426},
doi = {10.1111/cen.15300}
}
EUVIMED